Cct301-59
WebSafety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma Latest version (submitted October 19, 2024) on ClinicalTrials.gov A study version is represented by a row in the table. Select two study versions to compare. One each from columns A and B. WebJan 8, 2024 · CCT301-38 AXL and CCT301-59 ROR2 were evolved and molecularly engineered into CAR-T products to provide tumor microenvironment (TME) control over CAR-T receptor ligand binding, cytokine release, and cell lysis. Each cellular product additionally contains a cell removal epitope for antibody mediated removal.
Cct301-59
Did you know?
WebNov 22, 2024 · To assess the safety and tolerability of CCT301-38 cell therapy for patients with AXL-positive (IHC 1+ or greater in ≥50% tumor cells) relapsed or refractory sarcomas. Secondary Outcome Measures : ORR [ Time Frame: Up to 52 weeks ] WebMay 21, 2024 · The data, presented at the Association for Cancer Immunotherapy (CIMT) 2024 Annual Meeting, continues to support the feasibility, comparative safety and pharmacokinetics of dose escalation of two CAR-T products, CCT301-38 (AXL) and CCT301-59 (ROR2), in a single patient population.
WebMay 22, 2024 · The data, presented at the Association for Cancer Immunotherapy (CIMT) 2024 Annual Meeting, continues to support the feasibility, comparative safety and pharmacokinetics of dose escalation of two CAR-T products, CCT301-38 (AXL) and CCT301-59 (ROR2), in a single patient population. WebDescription This is a single arm, open label, dose escalation clinical study to evaluate the safety and preliminary therapeutic efficacy of CCT301-59 T cells in adult subjects with relapsed and refractory stage IV metastatic solid tumors (soft tissue sarcoma, gastric cancer, pancreatic cancer, bladder cancer etc.).
WebAnti-Ror2 (CCT301-59) h (CD28-CD3ζ) CAR, pCDCAR1 (CAR-ZP032) All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease. The vector of anti-Ror2 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human Ror2. WebDec 25, 2024 · Overview. This is a two arm, open-label, dose escalation and dose expansion clinical study to evaluate the safety and efficacy of infusion of autologous CCT301-38 or CCT 301-59 T cells in adult subjects with relapsed and refractory stage IV metastatic renal cell carcinoma.Subjects with ROR2 positive biopsy will receive CCT301-59.
WebDec 25, 2024 · During CCT301-59 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of …
WebIn addition, 1359 phase 1 trials of anticancer drugs were initiated, with an AAGR of 23%. Sixty-three phase 1 trials were global multicenter trials, accounting for less than 5% of the total number. Most global multicenter trials were sponsored by Chinese pharmaceutical enterprises (32 of 48 sponsors [67%]). corrugated sandwich packageWebMay 8, 2024 · Efficacy of CCT301-59 CAR T cell therapy Time Frame: Up to 52 weeks Objective response, such as complete response (CR), partial response (PR), stable … corrugated rubber sheetWebA Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors. Overview. Status: Active not recruiting: Phase: Phase 1: Sponsor: Shanghai PerHum Therapeutics Co., Ltd. Start date: May 2024: End date: June 2024: Enrollment: 18 participants: Identifiers: NCT03960060, CCT301-59-mST01: brawl stars apk download pcWebof two CAR-T products, CCT301-38 (AXL) and CCT301-59 (ROR2), in a single patient population. The umbrella clinical trial design being run at SPHCC (Shanghai Public Health Clinical Center) under the direction of lead investigator Tongyu Zhu, M.D., examines the first two CAR-T products in human clinical trial to use AND logic gate control technology. corrugated rusted metal panelsWebSep 1, 2024 · Chimeric antigen receptor modified T-cells (CAR-T) against ROR2-positive cancer cells (CCT301-38, CCT301-59) are currently being tested in phase 1/2 clinical trials as a treatment for different... brawl stars apk download new updateWebBrief Summary. This clinical study is to investigate the safety and tolerability of CAR modified autologous T cells (CCT301-59) in subjects with recurrent or refractory solid tumors. Detailed Description. This is a single arm, open label, dose escalation clinical study to evaluate the safety and preliminary therapeutic efficacy of CCT301-59 T ... corrugated sampleWebFor the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ exclusively supports the … brawl stars apk download free